facebook button Merck KEYLYNK-007: Nivolumab plus Olaparib for Patients with HRR Mutated Solid Tumors
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

Merck KEYLYNK-007: Nivolumab plus Olaparib for Patients with HRR Mutated Solid Tumors

Sponsor: Merck Sharp & Dohme Corp.

Protocol MK-7339-007: A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer.

Eligible patients will have a mutation in any one of the following genes: BRCA1, BRCA2; or a loss of heterozygosity score of ≥16

For more information please contact the clinical research department: 631-675-5075